KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Debt to Equity (2018 - 2025)

Historic Debt to Equity for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $0.02.

  • Castle Biosciences' Debt to Equity fell 524.44% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 524.44%. This contributed to the annual value of $0.02 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Castle Biosciences' Debt to Equity stood at $0.02, which was down 524.44% from $0.02 recorded in Q2 2025.
  • Castle Biosciences' Debt to Equity's 5-year high stood at $0.05 during Q1 2022, with a 5-year trough of $0.02 in Q3 2025.
  • For the 3-year period, Castle Biosciences' Debt to Equity averaged around $0.03, with its median value being $0.02 (2024).
  • Over the last 5 years, Castle Biosciences' Debt to Equity had its largest YoY gain of 524.44% in 2025, and its largest YoY loss of 830.24% in 2025.
  • Castle Biosciences' Debt to Equity (Quarter) stood at $0.05 in 2022, then tumbled by 58.1% to $0.02 in 2024, then fell by 2.15% to $0.02 in 2025.
  • Its Debt to Equity was $0.02 in Q3 2025, compared to $0.02 in Q2 2025 and $0.02 in Q1 2025.